These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 12826042)
1. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Martin AR; Carides AD; Pearson JD; Horgan K; Elmer M; Schmidt C; Cai B; Chawla SP; Grunberg SM Eur J Cancer; 2003 Jul; 39(10):1395-401. PubMed ID: 12826042 [TBL] [Abstract][Full Text] [Related]
2. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859 [TBL] [Abstract][Full Text] [Related]
3. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F; Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346 [TBL] [Abstract][Full Text] [Related]
4. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263 [TBL] [Abstract][Full Text] [Related]
5. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
6. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486 [TBL] [Abstract][Full Text] [Related]
7. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ; J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886 [TBL] [Abstract][Full Text] [Related]
8. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. Rapoport BL Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369 [TBL] [Abstract][Full Text] [Related]
10. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487 [TBL] [Abstract][Full Text] [Related]
11. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Dando TM; Perry CM Drugs; 2004; 64(7):777-94. PubMed ID: 15025555 [TBL] [Abstract][Full Text] [Related]
12. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996 [TBL] [Abstract][Full Text] [Related]
15. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study. Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459 [TBL] [Abstract][Full Text] [Related]
16. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Warr DG; Street JC; Carides AD Support Care Cancer; 2011 Jun; 19(6):807-13. PubMed ID: 20461438 [TBL] [Abstract][Full Text] [Related]
18. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773 [TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Hesketh PJ; Aapro M; Street JC; Carides AD Support Care Cancer; 2010 Sep; 18(9):1171-7. PubMed ID: 19756774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]